Melbourne, Australia: Starpharma (ASX:SPL; OCTQX:SPHRY) today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2011.

The cash balance at 30 September 2011 was $17m.  Total operating and investing cash outflow for the quarter was $2.1m.  Major activities during the quarter included:

• Positive End of Phase 2 meeting with the FDA, paving the way for commencement of the Phase 3 program for VivaGel^® for the treatment of Bacterial Vaginosis (BV);
• Commencement of the Phase 2 study of VivaGel^® for prevention of BV;
• Initial results of Starpharma’s internal agrochemical program demonstrating Starpharma’s Priostar^® dendrimers improve the performance of major agrochemical agents including glyphosate (the active ingredient in Roundup^®); and
• further studies of Starpharma’s dendrimer-Docetaxel formulation in the Company’s drug delivery program.

Starpharma also signed and commenced several new drug delivery and agrochemical partnered programs during the quarter.  The company now has a broad range of commercial partnerships in these two areas, including with Lilly, GSK, Elanco, and a number of undisclosed industry-leading partners.

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report ( pdf file, 165kb)